Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Blood ; 123(20): 3152-5, 2014 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-24652991

RESUMEN

The extracellular signal-regulated kinase (ERK) signaling pathway is activated in Langerhans cell histiocytosis (LCH) histiocytes, but only 60% of cases carry somatic activating mutations of BRAF. To identify other genetic causes of ERK pathway activation, we performed whole exome sequencing on purified LCH cells in 3 cases. One patient with wild-type BRAF alleles in his histiocytes had compound mutations in the kinase domain of ARAF. Unlike wild-type ARAF, this mutant was a highly active mitogen-activated protein kinase kinase in vitro and was capable of transforming mouse embryo fibroblasts. Mutant ARAF activity was inhibited by vemurafenib, a BRAF inhibitor, indicating the importance of fully evaluating ERK pathway abnormalities in selecting LCH patients for targeted inhibitor therapy.


Asunto(s)
Histiocitosis de Células de Langerhans/enzimología , Histiocitosis de Células de Langerhans/genética , Mutación , Proteínas Proto-Oncogénicas A-raf/genética , Animales , Células 3T3 BALB , Activación Enzimática , Histiocitosis de Células de Langerhans/patología , Humanos , Células de Langerhans/enzimología , Células de Langerhans/metabolismo , Células de Langerhans/patología , Sistema de Señalización de MAP Quinasas , Ratones , Proteínas Proto-Oncogénicas B-raf/genética
2.
PLoS One ; 14(9): e0222400, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31527903

RESUMEN

Langerhans cell histiocytosis (LCH) is characterized by the accumulation of Langerin (CD207)-expressing histiocytes. Mutational activation of mitogen-activated protein kinase pathway genes, in particular BRAF, drives most cases. To test whether activated BRAF is sufficient for the development of LCH, we engineered mice to express BRAF V600E under the control of the human Langerin promoter. These mice have shortened survivals, smaller lymphoid organs, absent Leydig cells, and fewer epidermal LCs than controls, but do not accumulate histiocytes. To test whether the absence of histiocyte proliferation could be due to oncogene-induced senescence, we engineered homozygous Pten loss in the same cells that expressed BRAF V600E. Like mice with intact Pten, these mice have shortened survivals, smaller thymi, and absent Leydig cells. However, loss of Pten also leads to the accumulation of CD207+ histiocytes in spleen, thymus, and some lymph nodes. While many CD207+ histiocytes in the thymus are CD8-, reminiscent of LCH cells, the CD207+ histiocytes in the spleen and lymph nodes are CD8+. These mice also accumulate large numbers of CD207- cells in the lamina propria (LP) of the small intestine. Both the lymphoid and LP phenotypes are likely due to human Langerin promoter-driven BRAF V600E expression in resident CD8+ dendritic cells in the former and LP dendritic cells in the latter and confirm that Pten loss is required to overcome inhibitory pathways induced by BRAF V600E expression. The complex phenotype of these mice is a consequence of the multiple murine cell types in which the human Langerin promoter is active.


Asunto(s)
Histiocitos/patología , Histiocitosis de Células de Langerhans/genética , Histiocitosis de Células de Langerhans/patología , Fosfohidrolasa PTEN/genética , Proteínas Proto-Oncogénicas B-raf/genética , Eliminación de Secuencia/genética , Animales , Antígenos de Superficie/genética , Linfocitos T CD8-positivos/patología , Proliferación Celular/genética , Células Dendríticas/patología , Humanos , Intestino Delgado/patología , Masculino , Ratones , Fenotipo , Regiones Promotoras Genéticas/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA